Moderna shares jump after better than expected ER report.

Up by around 9% now today.

In addition to the ER report, The FDA is due to make its decision on Moderna's RSV vaccine shot in less than two weeks. Moderna hopes to launch its vaccine for older adults this fall.

如果獲得批準，這將是Moderna繼Covid疫苗之後的第二個商業產品。

“我們超級興奮的原因有很多，”他說。“這是我們的第二個產品，所以我認為它有助於驗證mRNA，或Moderna，平台。我認為從mRNA的角度來看，這是世界上第二個產品，所以我們很受鼓舞，因為我們預計在今年上半年獲得批準。”Chief Financial Officer Jamey Mock told Investor's Business Daily in an interview.

 

這不是投資建議，YMYD

 

 

 

 

 

所有跟帖： 

• I predict its RSV vac is going to be a commercial flop -君子花農- ♂ (0 bytes) () 05/02/2024 postreply 10:45:40